|
|
|
| First Name: | Wesley | | Last Name: | Farris | | Title: | Assistant Professor | | Advanced Degrees: | MD | | Affiliation: | University of Pittsburgh | | Department: | Neurology/Pittsburgh Institute for Neurodegerative Disease | | Street Address 1: | 3501 Fifth Ave | | Street Address 2: | BST3-7019 | | City: | Pittsburgh | | State/Province: | PA | | Zip/Postal Code: | 02115 | Country/Territory: | U.S.A. | | Phone: | 412-383-5832 | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports no financial or other potential conflicts of interest. [Last Modified: 25 July 2007]
|
|
|
View all comments by Wesley Farris
|
Neurobiology, Epidemiology, Animal Models, Molecular and Cell biology, Clinical trials, A-beta PP/A-beta, Genetics, Drug screening, Neuropathology
|
Medical hospital, University
|
My lab is interested in the mechanisms and relevance of A-beta clearance in general, and A-beta proteolysis in particular. |
Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ and Guénette S. “Insulin-degrading enzyme regulates the levels of insulin, amyloid ß-protein, and the ß-amyloid precursor protein intracellular domain in vivo.” Proceedings of the National Academy of Sciences, U.S.A.. 2003; 100(7): 4165-4167.
(Featured in Science magazine’s News Focus, July 4, 2003 and Newsweek, Dec. 8, 2003; in top 10 cited AD reseach papers of 2003 per Nature Medicine July 2006).
Leissring MA, Lu A, Condron M, Teplow DB, Stein, RL, Farris W, Selkoe DJ. "Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays." Journal of Biological Chemistry. 2003; 278 (39): 37314-37320.
Farris W, Mansourian S, Leissring MA, Eckman EA, Eckman CB, and Selkoe DJ. “Diabetes-inducing mutations in insulin-degrading enzyme cause impaired degradation of neuronal amyloid ß-protein.” In Alzheimer’s Disease and Related Disorders: Research Advances. K. Iqbal and B. Winblad, editors. Ana Aslan International Academy of Aging. Bucharest, Romania. 2003.
Whitaker C, Eckman C, Almeida C, Feinstein D, Atwood C, Eckman E, Crutcher K, Hersh L, Leissring M, LaVoie M, Ertekin-Taner N, Shapiro P, Takahashi R, Yamin, R,Mansourian S, Estus S, Lesne S, Turner T, Farris W, Stroebel G. “Live discussion: Amyloid-beta degradation: the forgotten half of Alzheimer's disease.” Journal of Alzheimers Disease. 2003; 5(6):491-497. (W. Farris co-host of discussion)
Leissring MA, Farris W, Chang AY, Walsh, D, Wu X, Sun, X, Frosch MP, and Selkoe DJ. “Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.” Neuron. 2003; 40(6): 1087-1093.
Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi, RE, and Selkoe DJ. “Partial loss-of–function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid ß-protein.” American Journal of Pathology. 2004; 164: 1425-1434.
Leissring, MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, and Selkoe, DJ. "Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria." Biochemical Journal. 2004; 383: 439-446.
Farris W. (invited Contributing Editor) “Diabetes is associated with parkinsonism in older people.” Journal Watch Neurology. M.A. Samuels, editor. Massachusetts Medical Society, Waltham, MA. 2005; 7(1): 5.
Kulstad JJ, McMillan PJ, Leverenz JB, Cook DG, Green PS, Peskind ER, Wilkinson CW, Farris W, Mehta PD, Craft S. “Effects of Chronic Glucocorticoid Administration on Insulin-Degrading Enzyme and Amyloid-Beta Protein in the Aged Macaque.” Journal of Neuropathology and Experimental Neurology. 2005; 64(2): 139-146.
Farris W, Leissring MA, Hemming ML, Chang AY, and Selkoe DJ. “Alternative splicing of human insulin-degrading enzyme yields a novel isoform with decreased ability to degrade insulin and amyloid ß-protein.” Biochemisty. 2005; 44(17): 6513-1625.
Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE. “Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer’s disease families.” Journal of Biological Chemistry. 2007; 282(11): 7825-7832.
Hemming ML, Selkoe DJ, Farris W. “Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid-β protein metabolism in mouse models of Alzheimer disease.” Neurobiology of Disease. 2007; 26(1): 273-281.
Farris W, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. “Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy.” American Journal of Pathology. 2007 (in press).
|
Late onset AD is caused by problems with A-beta clearance. |
|
|
Home
